SCHEMBL8080233

SCHEMBL8080233

CCS(=O)(=O)NC(CN)C(=O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 3/20 0.36
ITGA2B P08514 3/20 0.36
TGFBR1 P36897 3/20 0.35
MMP2 P08253 3/20 0.33
MMP9 P14780 3/20 0.33
KDM4E B2RXH2 1/20 0.32
MAPT P10636 1/20 0.32
THRB P10828 1/20 0.32
ALOX15 P16050 1/20 0.32
NFKB1 P19838 1/20 0.32
PTGS2 P35354 1/20 0.32
THPO P40225 1/20 0.32
RECQL P46063 1/20 0.32
BLM P54132 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
GABRR1 P24046 3/20 0.32
LMNA P02545 1/20 0.32
CA2 P00918 1/20 0.32
FOLH1 Q04609 2/20 0.31
NAALAD2 Q9Y3Q0 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8091782 0.86 ITGB3 (0.42) ITGB3ITGA2BTGFBR1CA2
SCHEMBL7262649 0.83 ITGB3 (0.52) ITGB3ITGA2B
SCHEMBL7262653 0.83 ITGB3 (0.52) ITGB3ITGA2B
SCHEMBL7406599 0.79 ITGB3 (0.41) ITGB3ITGA2BTGFBR1ALDH1A1
SCHEMBL715191 0.79 CA2 (0.39) SMN1; SMN2CA2
SCHEMBL714149 0.79 CA2 (0.39) SMN1; SMN2CA2
SCHEMBL13253140 0.79 CA2 (0.39) SMN1; SMN2CA2
SCHEMBL20335027 0.78 ALDH1A1 (0.52) MMP2MMP9KDM4EMAPTLMNA
SCHEMBL7378230 0.78 GABRR1 (0.34) TGFBR1MMP2MMP9GABRR1LMNA
SCHEMBL20335026 0.78 ALDH1A1 (0.52) MMP2MMP9KDM4EMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1051625-A1 ASSESSING RISK FOR INTEGRIN ANTAGONIST/AGONIST MEDIATED DISEASES Du Pont Pharmaceuticals Company (US) 2000-11-15 EP disclosed
WO-1999038014-A1 ASSESSING RISK FOR INTEGRIN ANTAGONIST/AGONIST MEDIATED DISEASES DU PONT PHARMACEUTICALS COMPANY (US) 1999-07-29 WO disclosed